Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay
Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay
复制标题
DOI：
10.1128/jcm.43.12.5950-5956.2005
复制
发表时间：
2005-12-01
影响因子：
9.4
通讯作者：
Bremer, JW
中科院分区：
文献类型：
--
作者：
Jennings, C;Fiscus, SA;Bremer, JW
人类免疫缺陷病毒(HIV)RNA检测是监测HIV感染患者抗逆转录病毒治疗的金标准。然而，设备和试剂成本阻碍了该分析在资源有限的环境中广泛使用。Perkin-Elmer超灵敏p24试验和Cavidi Exavir负荷试验都为监测病毒载量提供了潜在的更简单、成本更低的技术。使用来自HIV阳性受试者的临床样本(B亚型)和添加HIV的样本(A、C、D、CRF_01AE、CRF_02AG和F)的面板，将这些检测与Roche Amplicor HIV-1监测测试v1.5进行比较。超灵敏的p24检测方法检测到病毒载量为250,000拷贝/毫升的添加样本的100%和病毒载量为219至288,850拷贝/毫升的临床样本的61%。如果在程序中加入外部裂解缓冲液，检测率将显著提高。卡维迪试验检测到了54%到100%的病毒载量为10000份/毫升的添加样本和68%的临床样本。该试剂盒的新版本也极大地提高了这些检测率。变异系数表明，每个试剂盒都具有良好的重复性。Cavidi v1.0、Cavidi v2.0和Perkin-Elmer以及Perkin-Elmer Plus外部缓冲器的结果都与罗氏监测测试的结果有很好的相关性(分别为r=0.83~0.96，r=0.84~0.99，r=0.58~0.67，r=0.59~0.95)。因此，在资源有限的情况下，使用这两种检测方法监测患者，再加上不那么频繁的确认检测，为频繁的艾滋病毒RNA检测提供了一种可行的替代方案。
Human immunodeficiency virus (HIV) RNA testing is the gold standard for monitoring antiretroviral therapy in HIV-infected patients. However, equipment and reagent costs preclude widespread use of the assay in resource-limited settings. The Perkin-Elmer Ultrasensitive p24 assay and the Cavidi Exavir Load assay both offer potentially simpler, less costly technologies for monitoring viral load. These assays were compared to the Roche Amplicor HIV-1 Monitor Test, v1.5, using panels of clinical samples (subtype B) from HIV-positive subjects and HIV-spiked samples (subtypes A, C, D, CRF_01AE, CRF_02AG, and F). The Ultrasensitive p24 assay detected 100% of the spiked samples with virus loads of > 250,000copies/ml and 61% of the clinical samples with virus loads of 219 to 288,850 copies/ml. Detection rates were improved substantially if an external lysis buffer was added to the procedure. The Cavidi assay detected 54 to 100% of spiked samples with virus loads > 10,000 copies/ml and 68% of the clinical samples. These detection rates were also greatly improved with a newly implemented version of this kit. Coefficients of variation demonstrate good reproducibility for each of these kits. The results from the Cavidi v1.0, Cavidi v2.0, and Perkin-Elmer, and the Perkin-Elmer Plus external buffers all correlated well with the results from the Roche Monitor Test (r = 0.83 to 0.96, r = 0.84 to 0.99, r = 0.58 to 0.67, and r = 0.59 to 0.95, respectively). Thus, the use of these two assays for monitoring patients, together with less-frequent confirmation testing, offers a feasible alternative to frequent HIV RNA testing in resource-limited settings.